既往缺血性卒中患者强化血压控制
该多中心、开放标签、随机试验在巴西30个中心纳入4368例血压升高且有缺血性卒中或TIA病史的患者,随机分入强化治疗组(目标收缩压<120 mmHg)或标准治疗组(目标收缩压<140 mmHg)。主要终点为心血管死亡、非致死性心肌梗死、非致死性卒中或因不稳定型心绞痛或心力衰竭住院的复合终点。中位随访3.9年,强化组主要终点事件发生率10.9%(3.25事件/100人年),标准组13.5%(4.11事件/100人年),HR 0.79(95%CI 0.67-0.94;P=0.007)。强化组复合肾脏结局更常见,两组严重不良事件总发生率相似。
要点
- 既往缺血性卒中或TIA且血压升高患者,强化降压至收缩压<120 mmHg较<140 mmHg降低主要心血管事件(HR 0.79;95%CI 0.67-0.94;P=0.007)。
- 随访排除前3个月后,强化组平均收缩压122.0±11.5 mmHg(中位119.6),标准组135.2±9.7 mmHg(中位135.0),组间平均差13.1 mmHg(95%CI 12.5-13.8)。
- 主要终点事件:强化组236例(10.9%;3.25事件/100人年)vs 标准组297例(13.5%;4.11事件/100人年)。
- 复合肾脏结局(eGFR持续下降≥50%或进展至终末期肾病)在强化治疗组更常见。
- 两组严重不良事件总发生率相似。
适用人群与场景
- 巴西30个中心纳入的血压升高且有既往缺血性卒中或短暂性脑缺血发作(TIA)病史的患者。
- 共4368例,强化治疗组2172例,标准治疗组2196例;平均年龄63.9±11.2岁,女性2093例(47.9%)。
诊断标准与关键阈值
- 强化治疗目标:收缩压<120 mmHg。
- 标准治疗目标:收缩压<140 mmHg。
处置流程与药物剂量
- 强化治疗组:目标收缩压<120 mmHg。
- 标准治疗组:目标收缩压<140 mmHg。
研究设计与关键结果
- 多中心、开放标签、随机试验,在巴西30个中心纳入4368例血压升高且既往缺血性卒中或TIA患者,随机分入强化治疗(目标收缩压<120 mmHg,2172例)或标准治疗(目标收缩压<140 mmHg,2196例)。
- 主要终点为心血管死亡、非致死性心肌梗死、非致死性卒中或因不稳定型心绞痛或心力衰竭住院的复合终点。
- 中位随访3.9年,主要终点事件强化组236例(10.9%;3.25事件/100人年)vs 标准组297例(13.5%;4.11事件/100人年),HR 0.79(95%CI 0.67-0.94;P=0.007)。
- 随访排除前3个月后,强化组平均收缩压122.0±11.5 mmHg(中位119.6 mmHg)vs 标准组135.2±9.7 mmHg(中位135.0 mmHg),组间平均差13.1 mmHg(95%CI 12.5-13.8)。
- 复合肾脏结局(eGFR持续下降≥50%或进展至终末期肾病)在强化治疗组更常见;两组严重不良事件总发生率相似。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于既往缺血性卒中或TIA且血压升高的患者,作者结论认为目标收缩压<120 mmHg较<140 mmHg可降低主要心血管事件发生率。
- 强化治疗组复合肾脏结局(eGFR持续下降≥50%或进展至终末期肾病)更常见,两组严重不良事件总发生率相似。
指南或共识出处
- OPTIMAL-STROKE试验(ClinicalTrials.gov NCT04036409),由Hospital Israelita Albert Einstein和巴西卫生部资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether intensive blood-pressure control reduces cardiovascular risk after cerebrovascular events remains uncertain.
METHODS: In this multicenter, open-label, randomized trial conducted at 30 sites in Brazil, we assigned participants with elevated blood pressure and previous ischemic stroke or transient ischemic attack to receive intensive treatment targeting a systolic blood pressure of less than 120 mm Hg or to receive standard treatment targeting a systolic blood pressure of less than 140 mm Hg. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina or heart failure.
RESULTS: A total of 4368 participants were enrolled, with 2172 assigned to intensive treatment and 2196 to standard treatment. The mean (±SD) age of the participants was 63.9±11.2 years, and 2093 (47.9%) were women. During the follow-up period, excluding the first 3 months, the mean systolic blood pressure was 122.0±11.5 mm Hg (median, 119.6 mm Hg) in the intensive-treatment group and 135.2±9.7 mm Hg (median, 135.0 mm Hg) in the standard-treatment group, with a between-group mean difference of 13.1 mm Hg (95% confidence interval [CI], 12.5 to 13.8). Over a median follow-up of 3.9 years, a primary-outcome event occurred in 236 participants (10.9%; 3.25 events per 100 person-years) with intensive treatment and in 297 (13.5%; 4.11 events per 100 person-years) with standard treatment (hazard ratio, 0.79; 95% CI, 0.67 to 0.94; P = 0.007). The composite renal outcome (sustained reduction of ≥50% in the estimated glomerular filtration rate or progression to end-stage renal disease) was more common with intensive treatment. The overall incidence of serious adverse events was similar in the two groups.
CONCLUSIONS: Among participants with previous ischemic stroke or transient ischemic attack, targeting a systolic blood pressure of less than 120 mm Hg resulted in a lower incidence of major cardiovascular events than targeting a systolic blood pressure of less than 140 mm Hg. (Funded by Hospital Israelita Albert Einstein and the Brazilian Ministry of Health; OPTIMAL-STROKE ClinicalTrials.gov number, NCT04036409.).
参考来源
- Sampaio Silva G, Machline-Carrion MJ, Santo K, et al. Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke. N Engl J Med. 2026. PMID: 43001741. doi:10.1056/NEJMoa2612924
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。